Analysts show high confidence in Theravance Biopharma's grow...

Analysts show high confidence in Theravance Biopharma's growth rate, predicting a breakeven point by 2026. The company's lack of debt, which is unusual for a loss-making pharma, reduces the risk around investing in the company.